Compare GE HealthCare Technologies Inc. Common Stock (GEHC) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE HealthCare Technologies Inc. Common Stock vs Xpeng Inc - ADR — how do they compare? GE HealthCare Technologies Inc. Common Stock trades at $68.66 (market cap $31.07B), while Xpeng Inc - ADR trades at $9.51 (market cap $9.24B). The key difference: GE HealthCare Technologies Inc. Common Stock is far larger — about 3.4× Xpeng Inc - ADR's market cap, and GE HealthCare Technologies Inc. Common Stock pays a 0.23% dividend while Xpeng Inc - ADR pays none. Which is the better fit depends on your goals.
| GEHC | XPEV | |
|---|---|---|
Market Cap | $31.07B | $9.24B |
Volume | 3,443,020 | 6,669,510 |
Sector | Health | Consumer Cyclical |
52-Week High | $88.16 | $28.07 |
52-Week Low | $59.48 | $9.25 |
Enterprise Value | $39.53B | $11.18B |
Dividend Yield | 0.23% | — |
Typical Hold Time | — | 81 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
XPeng (XPEV) trades at $9.42, down 2.48% amid bearish technical signals despite strong revenue growth. The company delivered 41,256 vehicles in September 2026 and is expanding globally with new model launches. While revenue surged to $76.72 billion in 2025, net losses persist at -$1.14 billion, though margins are improving. Analyst consensus remains bullish with a $17.55 price target.
Investment outlook balances growth potential against profitability challenges. XPeng's expansion into AI robotics and European markets offers upside, but persistent losses and competitive pressures pose risks. The stock presents a speculative opportunity for investors betting on future profitability and market share gains in the evolving EV sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GE HealthCare Technologies Inc. Common Stock
GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
